Northwire Canada EditionSaturday, July 11, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Production / Operations Routine +

Herbal Dispatch Completes First International Gummy Export, Generates $350,000 in Revenue and Advances Global Edibles Strategy

Export Milestone Validates Strategy But Revenue Impact Remains Marginal Relative to Losses

Executive Summary
  • Herbal Dispatch Inc. completed its first international export of medical cannabis gummies to Australia on April 30, 2026.
  • The shipment generated approximately $350,000 in revenue from a top three global cannabis company customer.
  • Products are compliant with Canadian federal regulations and GMP standards.
  • Management anticipates follow-on shipments in 2026 subject to regulatory approvals.
  • Existing international footprint includes Australia, Portugal, Germany, Brazil, Czech Republic, UK, Switzerland, and Costa Rica.
  • Domestic strategy continues to expand the "Chomp" brand edibles offerings within Canada.
  • Industry context provided includes Organigram Global Inc.'s acquisition of Sanity Group and British American Tobacco investment, signaling sector consolidation but not directly impacting Herbal Dispatch operations.
Material Impact
  • The $350,000 revenue from a single export tranche is immaterial relative to Full Year 2025 gross sales of $16.5 million (approx. 2% of annual run rate).
  • This announcement confirms execution capability for the "International B2B Exports" strategic pillar outlined in December 2025, but does not fundamentally alter the financial model.
  • The news is consistent with previous export milestones announced in January and February 2026 (Germany/Portugal shipments), indicating a steady progression rather than a sudden breakthrough.
  • No new financing or M&A activity was disclosed for Herbal Dispatch specifically; the Organigram/BT Tobacco news is sector-wide context.
  • The positive sentiment supports the stock but lacks the magnitude to justify a "Material - Positive" rating given the company's ongoing full-year losses and small absolute revenue contribution from this specific deal.
HERB · Price
Company Overview
  • Business Model: Cannabis distribution platform focusing on medical cannabis sales to veterans, recreational edibles ("Chomp" brand), and international B2B exports.
  • Flagship Project: Expansion of high-margin export channels (gummies/medical flower) to Europe and Australia combined with domestic e-commerce growth.
  • Market Position: Active in Canadian medical/recreational markets with growing international footprint; listed on CSE, Frankfurt Stock Exchange, and OTCQB (LUFFF).
  • Operational Status: Achieved positive Adjusted EBITDA in Q4 2025 ($100k) but reported negative full-year Adjusted EBITDA for 2025 (-$700k).
Read the original news release →

More from Herbal Dispatch Inc.